Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E. — Clinical Trial Site

183 Registered trials

80 Currently recruiting

Organisation

Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.

Location

Porto, Portugal

Identifier

ORG-100033662

Address

Rua Dr. Antonio Bernardino De Almeida, 4200-072, Portugal

Departments

-
#2000:Serviço Oncologia Médica
#2142: Serviço de Hematologia
#3002: Serviço de Oncologia Médica
#4000: Serviço de Oncologia Médica
#9000:Serviço de Oncologia Médica
1500 : Oncologia Médica
2101: Serviço de Oncologia Médica
2900: Serviço de Hematologia
3401:Serviço de Oncologia Médica
351007: Oncologia
35106: Oncologia
35108: Oncologia Medica
4401: Serviço de Oncologia Médica
5801:Anesthesiology/Reanimation
5805:Oncologia Medica
705: Oncologia Medica
93149007: Oncologia Medica
Bone Marrow Transplantation Service
Centro de Investigação
Clinical Hematology
Day Hospital
Departamento de Oncologia
Department of Hematology and Bone Marrow Transplant
Department: Medical Oncology
Hematologia
Hematologia Clínica
Hematologia e Transplantação de Medula
Hematology
Hematology and Bone Marrow Transplant Department
Hematology and bone marrow transplantation service
Hematology Department
INSTITUITO PORTUGUES DE ONCOLOGIA DO PORTO CLIN. ONCOL. IV( #22)
Medical Management
Medical Oncology
Medical oncology - Breast
Medical oncology - Ovarian
Medical Oncology Departament
Medical Oncology Department
Medical Oncology Service
N/A
NA
Not Applicable
Onco-Hematologia
Oncohematology
Oncologia
Oncologia Médica
Oncology
Oncology Department
Pediatric
Pediatric Service
Pediatrics
Reumatology
Service of Medical Oncology
Serviço de Gastrenterologia
Serviço de Hematologia e Transplantação de Medula Óssea
Serviço de Hematologia e Transplantação de Medula Ósses
Servico de Medicina Oncologica
Serviço de Onco-Hematologia
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Pediatria
Serviço de Urologia
Unidade de Investigação Clínica
Urology

Clinical trials at this site (183)

Search interface

A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending

2025-523869-22-00 advanced or metastatic extrapulmonary neuroendocrine ca 5
A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab i… Recruiting

2025-521712-19-00 Colorectal Cancer 5 2026-07-06
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 small cell lung cancer 5 2026-06-23
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting

2024-516476-15-00 Advanced gastrointestinal stromal tumor (GIST) 9 2026-03-04
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A… Recruiting

2024-518973-32-00 Chronic Graft-Versus-Host Disease 5 2025-07-03
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Acute myeloid leukemia 5 2025-05-05
A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting

2024-514459-14-00 Non-Small Cell Lung Cancer 4 2025-04-22
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Ovarian cancer recurrent 5 2025-04-11
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study Recruiting

2024-512217-40-00 Malignant Solid Tumors 10 2024-10-11
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Pat… Recruiting

2023-507536-21-00 Advanced Solid Tumors 7 2024-10-04
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 4 2024-10-02
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Small Cell Lung Cancer 4 2023-10-17
A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting

2022-502548-12-00 marginal zone lymphoma 5 2023-09-28
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Acute lymphoblastic leukemia 5 2022-12-15
A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting

2022-501374-19-00 Aggressive and Indolent B-cell Malignancies (mantle cel 4 2022-09-16
First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide… Recruiting

2023-503795-24-00 Avanced Non-Small Cell Lung Cancer 7 2022-09-16
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20